NewsRx

Search our medical news database

Liposomes

Anti-p185HER2 Immunoliposomes Developed for Cancer Therapy

Published in Cancer Weekly, April 3rd, 1995

Researchers from the University of California and Genentech, Inc., report that anti-p185HER2 immunoliposomes are a promising therapeutic vehicle for the treatment of p185HER2 overexpressing human cancers.

J.W. Park et al. remark that HER2 protooncogene and p185HER2, the growth factor receptor-tyrosine kinase it encodes, play a central role in the pathogenesis of many human cancers. Twenty to thirty percent of breast cancers have overexpression of p185HER2, which predicts a poor prognosis for these patients. The p185HER2 receptor is therefore an attractive target for antibody-based therapy ("Development of...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook